Inaddition, the RHAPSODY (Rilonacept inHibition of interleukin-1 Alpha and beta forrecurrent Pericarditis: a pivotal Symptomatology and Outcomes stuDY) trial withrilonacept — an IL-1α and IL-1β trap — has shown that IL-1blockade is able not only to resolve the acute flare of pericarditis rapidly butalso to decrease the risk of recurrences [9]. This evidence concerns the gene IL1A and pericarditis.